BYLOK

What this means for you

Registered since 03 Jan 2023. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

79339202

Registration number

6938347

Mark type

Stylized text

Filed

01 Feb 2022

Published for opposition

18 Oct 2022

Registered

03 Jan 2023

Attorney of record

LAWRENCE J CRAIN

Goods and services

• Class 001 — Chemicals: Biochemicals, namely, monoclonal and trimeric antibodies and derivatives thereof for in-vivo or in-vitro scientific research and development to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases and for use in laboratories, diagnostics and analytics for scientific or research use
• Class 005 — Pharmaceuticals: Pharmaceutical preparations based on human monoclonal or trimeric antibodies and derivatives thereof for treating cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, for use in related diagnostic or therapeutic use, and for use as medical diagnostic assays for testing of body fluids or tissues, for use in disease detection, including, cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases
• Class 009 — Scientific and electric apparatus: Downloadable computer software for scientific laboratory research and commercial use for applications with monoclonal or trimeric antibodies used to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, namely, software for an algorithm to generate antibody sequences
• Class 042 — Scientific and technological services: Medical and scientific research in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; medical research services, namely, protein engineering in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; pharmaceutical product development in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; industrial research in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; and contract research services in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; computer programming for acquisition and processing of medical data in the context of medical-scientific research, development and therapy with monoclonal or trimeric antibodies and their derivatives
• Class 045 — Legal and security services: Legal services in the field of patent exploitation, namely, patent licensing; licensing of intellectual property in the field of monoclonal and trimeric antibodies for laboratories, diagnostics and analytics for scientific or research use

Owner

• Lonza Ltd., CH
• Lonza Ltd., CH
• Lonza Ltd., CH

Prosecution history

• 12 Sept 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 12 Sept 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 12 Sept 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 17 May 2023 — FINAL DECISION TRANSACTION PROCESSED BY IB
• 20 Apr 2023 — FINAL DISPOSITION NOTICE SENT TO IB
• 20 Apr 2023 — FINAL DISPOSITION PROCESSED
• 03 Apr 2023 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
• 03 Jan 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
• 03 Jan 2023 — REGISTERED-PRINCIPAL REGISTER
• 18 Oct 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 18 Oct 2022 — PUBLISHED FOR OPPOSITION
• 28 Sept 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 21 Sept 2022 — REFUSAL PROCESSED BY IB
• 13 Sept 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 10 Sept 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED